Immunomodulatory activity of humanized anti–IL-7R monoclonal antibody RN168 in subjects with type 1 diabetes

Keyphrases

• Monoclonal Antibody 100%
• CD8+ 100%
• Type 1 Diabetes Mellitus (T1DM) 100%
• CD4+ 100%
• Humanized 100%
• Type I Diabetes 100%
• Immunomodulatory Activity 100%
• T Cell Activation 66%
• Treg 66%
• Naïve T Cells 66%
• Interleukin-7 (IL-7) 66%
• Effector Memory T Cells 66%
• Central Memory T Cells 66%
• Immunological Response 33%
• High Dose 33%
• Clinical Response 33%
• RNA-seq Analysis 33%
• T Cells 33%
• Pathologic 33%
• Dose Escalation 33%
• Autoimmune Disease 33%
• Occupancy 33%
• Immune Cells 33%
• Treatment-related Adverse Events 33%
• Near-complete 33%
• Anti-apoptotic Bcl-2 33%
• Tetanus Toxoid 33%
• Treatment-related 33%
• Downmodulation 33%
• T Cell Differentiation 33%
• T Cell Development 33%
• Phase Ib Study 33%
• Memory T Cells 33%
• Active Infection 33%
• IL-7R 33%
• Immunological Effects 33%
• PSTAT5 33%
• Naïve Cells 33%
• IL-7 Receptor 33%

Immunology and Microbiology

• CD8 100%
• Monoclonal Antibody 100%
• CD4 100%
• Interleukin 7 100%
• Memory T Cell 100%
• T Cell 66%
• Naive T Cell 66%
• Regulatory T Cell 66%
• Cytokine 33%
• Drug Megadose 33%
• Immunocompetent Cell 33%
• Immune Response 33%
• Cell Function 33%
• Autoimmune Disease 33%
• RNA Sequence 33%
• Bcl-2 33%
• Tetanus Vaccine 33%
• T Cell Development 33%
• Infection 33%